Chia-Tai Tianqing Pharma Group (CTTQ), a diversified China drug company headquartered in Jiangsu province, filed an IND with the CFDA to begin clinical trials of its Recombinant Human Coagulation Factor VIII (rhFVIII). CTTQ in-licensed rights to the product from Alphamab, a biotech located in Suzhou’s BioBay Park. The two companies have been collaborating on developing the product since 2010.
Help employers find you! Check out all the jobs and post your resume.
